Mixed Treatment Comparison Meta-Analysis of Aspirin, Warfarin, and New Anticoagulants for Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation

Clinical Therapeutics

Volumn 35, Issue 7, 2013, Pages

  Assiri, Abdullah ^a,b   Al Majzoub, Omar ^a   Kanaan, Abir O ^a   Donovan, Jennifer L ^a   Silva, Matthew ^a  

^a MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b KING KHALID UNIVERSITY   (Saudi Arabia)

Author keywords

Aspirin; Mixed treatment comparison; Network meta analysis; Novel anticoagulants; Stroke prevention; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; APIXABAN; CLOPIDOGREL; DABIGATRAN; EDOXABAN; RIVAROXABAN; WARFARIN;

ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; HEART ATRIUM FIBRILLATION; HUMAN; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; STATISTICAL MODEL; SYSTEMATIC REVIEW;

EID: 84880398329     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2013.05.011     Document Type: Article

References (67)

1. Go A.S., Hylek E.M., Phillips K.A., et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001, 285:2370-2375.
2. Stewart S., Hart C.L., Hole D.J., McMurray J.J. Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study. Heart 2001, 86:516-521.
3. Sturm J.W., Davis S.M., O'Sullivan J.G., et al. The Avoid Stroke as Soon as Possible (ASAP) general practice stroke audit. Med J Aust 2002, 176:312-316.
4. Ntaios G., Manios E., Synetou M., et al. Prevalence of atrial fibrillation in Greece: the Arcadia Rural Study on Atrial Fibrillation. Acta Cardiol 2012, 67:65-69.
5. Gunarathne A., Patel J.V., Gammon B., et al. Ischemic stroke in South Asians: a review of the epidemiology, pathophysiology, and ethnicity-related clinical features. Stroke 2009, 40:e415-e423.
6. Jeong J.H. Prevalence of and risk factors for atrial fibrillation in Korean adults older than 40 years. J Korean Med Sci 2005, 20:26-30.
7. Chiang C.E., Naditch-Brule L., Murin J., et al. Distribution and risk profile of paroxysmal, persistent, and permanent atrial fibrillation in routine clinical practice: insight from the real-life global survey evaluating patients with atrial fibrillation international registry. Circ Arrhythm Electrophysiol 2012, 5:632-639.
8. Ohsawa M,Okayama A, Sakata K, et al. Rapid increase in estimated number of persons with atrial fibrillation in Japan: an analysis from national surveys on cardiovascular diseases in 1980, 1990 and 2000. J Epidemiol. 2005;15:194-196.
9. Lip G.Y., Brechin C.M., Lane D.A. The global burden of atrial fibrillation and stroke: a systematic review of the epidemiology of atrial fibrillation in regions outside North America and Europe. Chest 2012, 142:1489-1498.
10. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med. 11 1994;154:1449-1457.
11. Loewen P., Dahri K. Risk of bleeding with oral anticoagulants: an updated systematic review and performance analysis of clinical prediction rules. Ann Hematol 2011, 90:1191-1200.
12. Lip G.Y., Frison L., Halperin J.L., Lane D.A. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. J Am Coll Cardiol 2011, 57:173-180.
13. Ruiz-Gimenez N., Suarez C., Gonzalez R., et al. Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost 2008, 100:26-31.
14. Fang M.C., Go A.S., Chang Y., et al. A new risk scheme to predict warfarin-associated hemorrhage: the ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol 2011, 58:395-401.
15. Serebruany V., Rao S.V., Silva M.A., et al. Correlation of inhibition of platelet aggregation after clopidogrel with post discharge bleeding events: assessment by different bleeding classifications. Eur Heart J 2010, 31:227-235.
16. Furie K.L., Kasner S.E., Adams R.J., et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011, 42:227-276.
17. Furie K.L., Goldstein L.B., Albers G.W., et al. Oral antithrombotic agents for the prevention of stroke in nonvalvular atrial fibrillation: a science advisory for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2012, 43:3442-3453.
18. Gage B.F., Waterman A.D., Shannon W., et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001, 285:2864-2870.
19. Gage B.F., van Walraven C., Pearce L., et al. Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. Circulation 2004, 110:2287-2292.
20. Comparison of 12 risk stratification schemes to predict stroke in patients with nonvalvular atrial fibrillation. Stroke. 2008;39:1901-1910.
21. Hart R.G., Halperin J.L., Pearce L.A., et al. Lessons from the Stroke Prevention in Atrial Fibrillation trials. Ann Intern Med 2003, 138:831-838.
22. Lip G.Y., Nieuwlaat R., Pisters R., et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation. Chest 2010, 137:263-272.
23. You J.J., Singer D.E., Howard P.A., et al. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012, 141(Suppl):e531S-e575S.
24. Cooper N.J., Sutton A.J., Lu G., Khunti K. Mixed comparison of stroke prevention treatments in individuals with nonrheumatic atrial fibrillation. Arch Intern Med 2006, 166:1269-1275.
25. Jadad A.R., Moore R.A., Carroll D., et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 1996, 17:1-12.
26. Lu G., Ades A.E. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 2004, 23:3105-3124.
27. Lu G., Ades A.E. Assessing evidence inconsistency in mixed treatment comparisons. J Am Statist Assoc 2006, 101:447-459.
28. Woods B.S., Hawkins N., Scott D.A. Network meta-analysis on the log-hazard scale, combining count and hazard ratio statistics accounting for multi-arm trials: a tutorial. BMC Med Res Methodol 2010, 10:54.
29. van Valkenhoef G., Tervonen T., Zwinkels T., et al. ADDIS: a decision support system for evidence-based medicine. Decision Support Systems 2012, 55:459-475.
30. Caldwell D.M., Ades A.E., Higgins J.P. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ 2005, 331:897-900.
31. Lumley T. Network meta-analysis for indirect treatment comparisons. Stat Med 2002, 21:2313-2324.
32. Salanti G., Higgins J.P., Ades A.E., Ioannidis J.P. Evaluation of networks of randomized trials. Stat Methods Med Res 2008, 17:279-301.
33. Salanti G., Kavvoura F.K., Ioannidis J.P. Exploring the geometry of treatment networks. Ann Intern Med 2008, 148:544-553.
34. Dias S., Welton N.J., Caldwell D.M., Ades A.E. Checking consistency in mixed treatment comparison meta-analysis. Stat Med 2010, 29:932-944.
35. Petersen P., Boysen G., Godtfredsen J., et al. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet 1989, 1:175-179.
36. Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation. 1991;84:527-539.
37. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet. 1994;343:687-691.
38. Ezekowitz M.D., Bridgers S.L., James K.E., et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. N Engl J Med 1992, 327:1406-1412.
39. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group. Lancet. 1993;342:1255-1262.
40. Posada I.S., Barriales V. Alternate-day dosing of aspirin in atrial fibrillation. LASAF Pilot Study Group. Am Heart J 1999, 138(1 Pt 1):137-143.
41. Edvardsson N., Juul-Moller S., Omblus R., Pehrsson K. Effects of low-dose warfarin and aspirin versus no treatment on stroke in a medium-risk patient population with atrial fibrillation. J Intern Med 2003, 254:95-101.
42. Connolly S., Pogue J., Hart R., et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006, 367:1903-1912.
43. Sato H., Ishikawa K., Kitabatake A., et al. Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation: Japan Atrial Fibrillation Stroke Trial. Stroke 2006, 37:447-451.
44. Ezekowitz M.D., Reilly P.A., Nehmiz G., et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am J Cardiol 2007, 100:1419-1426.
45. Mant J., Hobbs F.D., Fletcher K., et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 2007, 370:493-503.
46. Rash A., Downes T., Portner R., et al. A randomised controlled trial of warfarin versus aspirin for stroke prevention in octogenarians with atrial fibrillation (WASPO). Age Ageing 2007, 36:151-156.
47. Connolly S.J., Pogue J., Hart R.G., et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 2009, 360:2066-2078.
48. Connolly S.J., Ezekowitz M.D., Yusuf S., et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009, 361:1139-1151.
49. Weitz J.I., Connolly S.J., Patel I., et al. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost 2010, 104:633-641.
50. Connolly S.J., Eikelboom J., Joyner C., et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011, 364:806-817.
51. Chung N., Jeon H.K., Lien L.M., et al. Safety of edoxaban, an oral factor Xa inhibitor, in Asian patients with non-valvular atrial fibrillation. Thromb Haemost 2011, 105:535-544.
52. Granger C.B., Alexander J.H., McMurray J.J., et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011, 365:981-992.
53. Ogawa S., Shinohara Y., Kanmuri K. Safety and efficacy of the oral direct factor xa inhibitor apixaban in Japanese patients with non-valvular atrial fibrillation. The ARISTOTLE-J study. Circ J 2011, 75:1852-1859.
54. Patel M.R., Mahaffey K.W., Garg J., et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011, 365:883-891.
55. Yamashita T., Koretsune Y., Yasaka M., et al. Randomized, multicenter, warfarin-controlled phase II study of edoxaban in Japanese patients with non-valvular atrial fibrillation. Circ J 2012, 76:1840-1847.
56. Hart R.G., Benavente O., McBride R., Pearce L.A. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999, 131:492-501.
57. Aguilar M., Hart R. Antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. Cochrane Database Syst Rev 2005, 4:CD001925.
58. Hart R.G., Pearce L.A., Aguilar M.I. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007, 146:857-867.
59. Segal J.B., McNamara R.L., Miller M.R., et al. Prevention of thromboembolism in atrial fibrillation. A meta-analysis of trials of anticoagulants and antiplatelet drugs. J Gen Intern Med 2000, 15:56-67.
60. Reynolds M.W., Fahrbach K., Hauch O., et al. Warfarin anticoagulation and outcomes in patients with atrial fibrillation: a systematic review and meta analysis. Chest 2004, 126:1938-1945.
61. Owen A. Antithrombotic treatment for the primary prevention of stroke in patients with non valvular atrial fibrillation: a reappraisal of the evidence and network meta analysis. Int J Cardiol 2010, 142:218-223.
62. Dentali F., Riva N., Crowther M., et al. Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature. Circulation 2012, 126:2381-2391.
63. van Walraven C., Jennings A., Oake N., et al. Effect of study setting on anticoagulation control: a systematic review and metaregression. Chest 2006, 129:1155-1166.
64. Connolly S.J., Pogue J., Eikelboom J., et al. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 2008, 118:2029-2037.
65. Fuster V., Ryden L.E., Cannom D.S., et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2011, 123:e269-e367.
66. Witt D.M., Sadler M.A., Shanahan R.L., et al. Effect of a centralized clinical pharmacy anticoagulation service on the outcomes of anticoagulation therapy. Chest 2005, 127:1515-1522.
67. Ansell J., Hollowell J., Pengo V., et al. Descriptive analysis of the process and quality of oral anticoagulation management in real-life practice in patients with chronic non-valvular atrial fibrillation: the International Study of Anticoagulation Management (ISAM). J Thromb Thrombolysis 2007, 23:83-91.